Skip to main content
. 2022 Jan 4;2022(1):CD013345. doi: 10.1002/14651858.CD013345.pub2

Zhu 2013b.

Methods Study design: Randomised clinical trial
Study duration: March 2008 to June 2009
Duration of follow‐up: 3 years
Setting: Hospital
Participants Age (mean ± SD, range): TACE + MWA: 53.6 years, 27‐80 years; TACE alone: 51.2 years, 28‐79 years
Male (n/total): TACE + MWA: 12/18; TACE alone: 11/18
Interventions TACE + MWA group (n = 18):
TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation A total of 2‐4 sessions of TACE were performed, with an interval of 3‐4 weeks.
MWA: Output power of 50‐80 W, 4‐10 minutes per ablation session
TACE group (n = 18):
TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation. A total of 2‐4 episodes of TACE were performed, with an interval of 3‐4 weeks.
Outcomes Serum level of AFP
1‐, 2‐, and 3‐year survival rates
Notes Country of study: China
Source of funding: None
There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.